KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Non-Current Debt: 2011-2021

Historic Non-Current Debt for Supernus Pharmaceuticals (SUPN) over the last 3 years, with Dec 2021 value amounting to $379.3 million.

  • Supernus Pharmaceuticals' Non-Current Debt was N/A to $379.3 million in Q4 2021 from the same period last year, while for Dec 2021 it was $379.3 million, marking a year-over-year change of. This contributed to the annual value of $379.3 million for FY2021, which is N/A change from last year.
  • Per Supernus Pharmaceuticals' latest filing, its Non-Current Debt stood at $379.3 million for FY2021, which was up 3,320.38% from $11.1 million recorded in FY2012.
  • Supernus Pharmaceuticals' 5-year Non-Current Debt high stood at $379.3 million for FY2021, and its period low was $379.3 million during FY2021.
  • Moreover, its 1-year median value for Non-Current Debt was $379.3 million (2021), whereas its average is $379.3 million.